Journal of Clinical Oncology, Vol 12, 176-183, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

PJ Stiff, RS McKenzie, DS Alberts, JA Sosman, JR Dolan, N Rad and T McCloskey
Department of Medicine, Loyola University Medical Center, Maywood, IL 60153.

PURPOSE: To develop an active high-dose chemotherapy regimen for the treatment of ovarian carcinoma. Due to the rapid development a drug resistance, conventional chemotherapy cures only 20% of patients with advanced disease. However, in vitro data demonstrate a steep dose- response curve to a variety of agents, most notably mitoxantrone. PATIENTS AND METHODS: A phase I study of escalated bolus mitoxantrone (10 to 25 mg/m2 x 3) and cyclophosphamide (30 to 50 mg/kg x 3) with a 5- day infusion of carboplatin (1,500 mg/m2) and an autologous bone marrow transplant (ABMT) was performed. Mitoxantrone pharmacokinetics were performed to document levels required to kill platinum-resistant ovarian carcinoma in vitro. RESULTS: We treated 25 patients; the maximum-tolerated total doses (MTD) were 75 mg/m2 for mitoxantrone, 120 mg/kg for cyclophosphamide, and 1,500 mg/m2 for carboplatin. The dose- limiting toxicity was gastrointestinal, with severe diarrhea, ileus, and resulting sepsis. Transient partial deafness was seen in four patients, and acute renal failure (ARF) occurred in one patient at the first dose level, but was eliminated in subsequent patients with aggressive hydration. There were four early deaths due to ARF (n = 1), Legionella pneumonia (n = 1), and sepsis (n = 2). Peak mitoxantrone levels at the MTD were 623 to 2,810 ng/mL, and the area under the curve (AUC) values of the concentration versus time measurements were 560 to 1,700 ng/mL/h. Of 20 assessable patients, 65% responded, with a 45% complete remission (CR) rate. All six of the assessable patients with ovarian cancer responded: CR in five (83%) and partial remission (PR) in one (17%); the CRs have lasted 7 to 30+ months. Responses were also seen in testicular and breast carcinoma. CONCLUSION: This regimen was well tolerated at the MTD and appears promising for relapsed/refractory ovarian carcinoma, with mitoxantrone levels achieved that are active in vitro against platinum-resistant ovarian carcinoma cells.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T.-Y. Chen, H. H. W. Chen, W.-C. Su, and C.-J. Tsao High-dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients with Nasopharyngeal Cancer: a Feasibility Study Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 331 - 335. [Abstract] [Full Text] [PDF]

				P. J. Stiff, J. Veum-Stone, H. M. Lazarus, L. Ayash, J. R. Edwards, A. Keating, J. P. Klein, D. J. Oblon, T. C. Shea, S. Thome, et al. High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report Ann Intern Med, October 3, 2000; 133(7): 504 - 515. [Abstract] [Full Text] [PDF]

				A. Patnaik, J. MacKinnon, P. Goss, T. Nagy, K. Stewart, A. Keating, and M. Crump Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer J. Clin. Oncol., June 12, 2000; 18(12): 2363 - 2368. [Abstract] [Full Text] [PDF]

				R. Advani, H. I. Saba, M. S. Tallman, J. M. Rowe, P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis, et al. Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) Blood, February 1, 1999; 93(3): 787 - 795. [Abstract] [Full Text] [PDF]

				T. Makatsoris and M. V. Seiden High-Dose Therapy for Ovarian Carcinoma Oncologist, October 1, 1997; 2(5): 330 - 339. [Abstract] [Full Text] [PDF]